Something fundamental shifted in weight-loss surgery over the past three years, and every bariatric clinic in Australia has felt it. Ozempic, Wegovy and Mounjaro moved from medical journals to dinner-table conversation, and patients who once viewed surgery as their only serious option now start with a prescription instead.
The numbers back it up. A JAMA Surgery analysis found US metabolic bariatric surgery utilisation fell 34% between 2022 and 2025, while GLP-1 prescriptions rose 140% over the same period. Separate US data presented to the ASMBS showed procedures dropped roughly 23% from their 2022 peak. Australia hasn’t published equivalent national figures, but Australian surgeons report the same pattern — and with Wegovy available here, the pressure on referrals is familiar to any bariatric practice.
So does that mean weight-loss surgery clinic marketing is a losing game? Not remotely. It means the old playbook is finished, and clinics that adapt have a genuine advantage.
The opportunity most clinics are missing
Here’s what the panic overlooks: obesity remains dramatically undertreated. The same JAMA Surgery research found only about 9.5% of the relevant population is receiving any treatment — drugs or surgery. Australia has a well-documented shortfall in bariatric surgery capacity relative to demand across both the public and private systems.
The patients haven’t disappeared. They’ve simply changed how they arrive. Many now come to you after GLP-1s — having regained weight after stopping, hit a plateau, or found the ongoing cost unsustainable (Wegovy sits around $460 a month in Australia, well beyond many budgets). Others need surgery clinically but don’t understand why. As one bariatric surgeon put it, the debate has become too polarised: surgery isn’t obsolete, and drugs aren’t a universal answer.
Your marketing’s job in 2026 is to meet patients in that far more complicated decision.
1. Own the comparison search
Patients are actively googling “gastric sleeve vs Ozempic,” “is weight-loss surgery still worth it,” and “what happens when I stop Wegovy.” Most Australian clinics have published nothing on these questions — which makes them the single biggest bariatric surgery SEO opportunity available. Honest, balanced comparison content that acknowledges GLP-1s’ real benefits and explains surgery’s durability builds enormous trust with an audience that is sick of being sold to. Well-researched content is now your strongest acquisition asset.
2. Market to the post-GLP-1 patient
This is the fastest-growing segment in obesity clinic marketing across Australia, and almost nobody is speaking to it. Build a dedicated page for patients who’ve tried GLP-1s and regained weight. Addressing it without judgement — weight regain after stopping medication is a well-documented clinical reality, not a personal failure. This is a warm, high-intent audience already convinced they need help.
3. Reframe your service as obesity care, not just surgery
Forward-thinking clinics no longer position themselves as “surgery clinics” but as comprehensive obesity treatment providers — offering GLP-1 pathways, surgery, and combined approaches. That’s a bigger addressable market, and it aligns with how modern obesity medicine actually works. It also opens up GLP-1 clinic marketing as a legitimate patient entry point rather than a competitor.
4. Use paid search for high-intent decisions
Weight loss clinic Google Ads still convert strongly, because bariatric searches carry serious intent and high patient value. The shift is in the messaging: campaigns focused on consultation and assessment (“find out which option suits you”) outperform outcome-led ads, and they’re far safer from a compliance standpoint. Our search engine marketing team builds campaigns around qualified enquiries, not clicks.
5. Convert the long consideration period
Bariatric patients research for months. Without follow-up, most enquiries simply go cold. Automated nurture — educational sequences, seminar invitations, reminders — is where weight loss surgery patient leads are won or lost. A fast, credible clinic website with clear surgeon credentials, transparent pricing guidance and easy booking does the heavy lifting while your team is in theatre.
Stay compliant while you grow
Bariatric surgeons and clinics are regulated health practitioners, so AHPRA’s advertising rules apply: no patient testimonials, no misleading claims, no unrealistic expectations, and real care with before-and-after imagery. GLP-1s are prescription-only medicines, which means you cannot advertise them by brand name to the public under Australian therapeutic goods law — refer to them generically. Compliant marketing isn’t a handbrake; in a sector this scrutinised, it’s a trust signal.
Ready to grow in the new landscape?
The GLP-1 era hasn’t ended weight-loss surgery — it’s reshuffled it. The clinics winning in 2026 are the ones telling a more honest, more useful story than “book your surgery today.”
At Jarvis Technologies, we help Australian bariatric and obesity clinics attract better-qualified patients through SEO, compliant paid search, education-led content and automation that nurtures long decisions into booked consultations. Book your free growth strategy call, and let’s build a strategy fit for the market as it is now — not as it was in 2021.
Frequently Asked Questions
Are GLP-1 drugs killing demand for weight-loss surgery in Australia?
They’ve reduced it, but not eliminated it. US data shows bariatric surgery utilisation fell 34% from 2022 to 2025 as GLP-1 prescriptions surged, and Australian clinics report similar pressure. However, obesity remains heavily undertreated — only around 9.5% of the relevant population receives any treatment — and Australia has a well-documented shortfall in bariatric surgery capacity.
How should bariatric clinics market themselves in the GLP-1 era?
Shift from selling surgery to guiding decisions. Publish honest comparison content, target patients who’ve regained weight after stopping GLP-1s, reposition as a comprehensive obesity care provider rather than a surgery-only clinic, and use paid search focused on consultations rather than outcomes.
Can bariatric clinics advertise Ozempic or Wegovy by name?
No. GLP-1 medicines are prescription-only, and Australian therapeutic goods law prohibits advertising prescription-only substances to the public. Refer to them generically — for example, “weight-loss medication” or “GLP-1 therapy” — rather than by brand name in public-facing marketing.
What’s the best way to get more weight-loss surgery patient leads?
Combine bariatric surgery SEO for the research-phase searches patients actually make, Google Ads for high-intent enquiries, and automated nurture for the long consideration period. Bariatric patients typically research for months, so clinics that follow up consistently convert far more of the enquiries they already receive.
Do AHPRA advertising rules apply to weight-loss surgery clinics?
Yes. Bariatric surgeons and clinics are regulated health practitioners, so patient testimonials can’t be used in advertising, claims must not be misleading or create unrealistic expectations, and before-and-after imagery is tightly restricted. Compliant, education-led marketing is both safer and more effective.